 |
|
|
Iclazepam
|
|
| Systematic (IUPAC) name | |
| 7-chloro-1-[2-(cyclopropylmethoxy)ethyl]-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one | |
| Identifiers | |
| CAS number | |
| ATC code | none |
| PubChem | |
| Chemical data | |
| Formula | C21H21ClN2O2 |
| Mol. mass | 368.857 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Iclazepam (Clazepam) is a drug which is a benzodiazepine derivative. It has sedative and anxiolytic effects similar to those produced by other benzodiazepine derivatives, and is around the same potency as chlordiazepoxide.
Iclazepam is a derivative of nordazepam substituted with a cyclopropylmethoxyethyl group on the N1 nitrogen. Once in the body, iclazepam is quickly metabolised to nordazepam and its N-(2-hydroxyethyl) derivative, which are thought to be mainly responsible for its effects.[1]
See also
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
References
- ^ Giudicelli JF, Berdeaux A, Idrissi N, Richer C. Clazepam: pharmacokinetics and effects on performance. British Journal of Clinical Pharmacology. 1978 Jan;5(1):65-9.
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
